Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
AUTOR(ES)
Suwaidi, Jassim Al
FONTE
BioMed Central
RESUMO
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=59641Documentos Relacionados
- Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.
- Effects of glycoprotein IIb/IIIa blockers
- Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
- Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
- Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.
